摘要
利妥昔单抗主要用于治疗B细胞淋巴瘤和广泛的自身免疫疾病。不幸的是,血脑屏障阻碍了利妥昔单抗在中枢神经系统(CNS)中发挥作用。多发性硬化(MS)的增长阶段是一种以炎症的鞘内划分抵制所有可用的免疫抑制治疗为特征的典型的中枢神经系统自身免疫学疾病。因此,鞘内治疗是治疗增长型MS的一种有希望的新兴疗法。我们首先对收集到的从外鞘内使用利妥昔单抗治疗中枢神经系统淋巴瘤的人类标本的动物模型和人类标本的数据进行了综述,然后总结了支持在多发性硬化症中使用鞘内利妥昔单抗治疗的必要性的证明材料。这篇综述给中枢神经系统自身免疫的进一步研究提供了一些有价值的初步数据。
关键词: 慢性发展,鞘内注射,淋巴瘤,多发性硬化,利妥昔单抗
Current Drug Targets
Title:Intrathecal Rituximab Therapy in Multiple Sclerosis: Review of Evidence Supporting the Need for Future Trials
Volume: 15 Issue: 13
Author(s): Mickael Bonnan, Sylvie Ferrari, Eric Bertandeau, Stephanie Demasles, Elsa Krim, Marie Miquel and Bruno Barroso
Affiliation:
关键词: 慢性发展,鞘内注射,淋巴瘤,多发性硬化,利妥昔单抗
摘要: Rituximab has demonstrated a major effect in B-cell lymphoma and in a wide range of autoimmune disorders. Unfortunately, the blood-brain-barrier excludes the disorders restricted to the central nervous system (CNS) from the action of rituximab. The progressive phase of multiple sclerosis (MS) is a prototypical CNS autoimmune disorder characterized by an intrathecal compartmentalization of inflammation resisting all the available immunosuppressive treatments. As a consequence, intrathecal therapeutics are promising new approach in progressive MS. We first review data gathered from animal models and human off-label intrathecal rituximab use in CNS lymphomas, then summarize the recent evidence supporting the need for trials based on the intrathecal use of rituximab in multiple sclerosis. The experience obtained in these settings offers valuable preliminary data for future studies in CNS autoimmunity.
Export Options
About this article
Cite this article as:
Mickael Bonnan, Sylvie Ferrari, Eric Bertandeau, Stephanie Demasles, Elsa Krim, Marie Miquel and Barroso Bruno, Intrathecal Rituximab Therapy in Multiple Sclerosis: Review of Evidence Supporting the Need for Future Trials, Current Drug Targets 2014; 15 (13) . https://dx.doi.org/10.2174/1389450115666141029234644
DOI https://dx.doi.org/10.2174/1389450115666141029234644 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ultrasound-Based Multimodal Molecular Imaging and Functional Ultrasound Contrast Agents
Current Pharmaceutical Design Preparation and Primary Bioevaluation of 99mTc-labeled-1-thio-β-D-Glucose as Melanoma Targeting Agent
Current Radiopharmaceuticals Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis
Current Pharmaceutical Design Role of γ-Secretase Inhibitors for the Treatment of Diverse Disease Conditions through Inhibition of Notch Signaling Pathway
Current Drug Targets Effects of Tyrosine Kinase Inhibitors on Growth and Bone Metabolism in Children with Haematologic Malignancies
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeted Therapy of Multiple Myeloma: The Changing Paradigm at the Beginning of the New Millennium
Current Cancer Drug Targets The Novel Role of the B-Cell Lymphoma/Leukemia 11A (BCL11A) Gene in β-Thalassaemia Treatment
Cardiovascular & Hematological Disorders-Drug Targets Dendritic Cells and the Promise of Therapeutic Vaccines for Human Immunodeficiency Virus (HIV)-1
Current HIV Research Mitochondrial Biogenesis Inhibitors for Anticancer Therapy: A Review of Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Exploring Therapeutic Potential of 1,3,4-Oxadiazole Nucleus as Anticancer Agents: A Mini-review
Medicinal Chemistry The Role of NF-κB Inhibitors in Cell Response to Radiation
Current Medicinal Chemistry Mechanisms of Anorexia Cancer Cachexia Syndrome and Potential Benefits of Traditional Medicine and Natural Herbs
Current Pharmaceutical Biotechnology P-Selectin Glycoprotein Ligand-1 as a Potential Target for Humoral Immunotherapy of Multiple Myeloma (Supplementry Material)
Current Cancer Drug Targets Preclinical Development of Novel Anti-Glioma Drugs Targeting the Endoplasmic Reticulum Stress Response
Current Pharmaceutical Design Future Prospects for Targeted Alpha Therapy
Current Radiopharmaceuticals Methotrexate Induced Pneumonitis: A Review Article
Current Respiratory Medicine Reviews 5' Adenosine Monophosphate-Activated Protein Kinase Modulators as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Prediction and Monitoring of Therapeutic Response by Molecular Imaging
Current Medical Imaging Curcumin: Structure-Activity Relationship Towards its Role as a Versatile Multi-Targeted Therapeutics
Mini-Reviews in Organic Chemistry Anticancer α-Helical Peptides and Structure / Function Relationships Underpinning Their Interactions with Tumour Cell Membranes
Current Protein & Peptide Science